Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F08%3A00208826" target="_blank" >RIV/00216208:11150/08:00208826 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes

Popis výsledku v původním jazyce

Percutaneous angiography with iodinated contrast in patients with chronic kidney disease carries a risk of contrast nephropathy, which is independently associated with increased mortality. Gadolinium contrast is a potential safe alternative to iodinatedcontrast for percutaneous transluminal renal angioplasty (PTRA). We compared the outcomes in patients with serum creatinine (Cr) >/= 176 micromol/L (2 mg/dL), who had either gadolinium (n = 57), iodinated (n = 68) or a combination of gadolinium and iodinated-contrast-enhanced (n = 38) PTRA. All patients had similar degrees of pre-procedural renal insufficiency. According to our results, gadolinium contrast is (when compared to iodinated contrast) associated with a significantly lower incidence of contrast nephropathy and early progression to end-stage renal disease (ESRD) in patients with pre-existing chronic kidney disease. The risk of fibrosing dermopathy remains to be established.

Název v anglickém jazyce

Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes

Popis výsledku anglicky

Percutaneous angiography with iodinated contrast in patients with chronic kidney disease carries a risk of contrast nephropathy, which is independently associated with increased mortality. Gadolinium contrast is a potential safe alternative to iodinatedcontrast for percutaneous transluminal renal angioplasty (PTRA). We compared the outcomes in patients with serum creatinine (Cr) >/= 176 micromol/L (2 mg/dL), who had either gadolinium (n = 57), iodinated (n = 68) or a combination of gadolinium and iodinated-contrast-enhanced (n = 38) PTRA. All patients had similar degrees of pre-procedural renal insufficiency. According to our results, gadolinium contrast is (when compared to iodinated contrast) associated with a significantly lower incidence of contrast nephropathy and early progression to end-stage renal disease (ESRD) in patients with pre-existing chronic kidney disease. The risk of fibrosing dermopathy remains to be established.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nephrology, Dialysis, Transplantation

ISSN

0931-0509

e-ISSN

—

Svazek periodika

23

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

000254472400026

EID výsledku v databázi Scopus

—